| Biomarker ID | 28 |
| PMID | 11757030 |
| Year | 2001 |
| Biomarker | Insulin |
| Biomarker Basis | Concentration Based (μIU/m) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in High Risk Group |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Vitamin B12 metabolism,Signaling events mediated by PTP1B,Selenium pathway,Amyloids,Folate metabolism |
| Experiment | High vs (Medium and Low) Risk |
| Type of Biomarker | Prognostic |
| Cohort | 112 patients were chosen for study and divided into 3 groups. Low Risk: 52 patients, Medium Risk: 16 patients, High Risk: 44 patients. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p= 0.05 |
| Method Used | Chemoluminescent assay |
| Clinical | No |
| Remarks | Low Risk: Serum PSA ≤ 10, stage ≤ T2a, or Gleason grade ≤ 6. Medium Risk: Serum PSA 10-15, Gleason =7 or stage ≤ T2b. High Risk: Gleason > 7, tumor in seminal vesicle biopsy, serum PSA > 15 or stage T2c or T3 |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | INS |